Today's Rundown Former Gilead CMO Cheng joins Akero as CEO, as company moves HQ Crescendo names ex-Roche leader Pisa as CMO Appeals court hands Broad Institute a win in CRISPR patent feud ImmusanT to develop Type 1 diabetes vaccine with JDRF backing Biodesy eyes expansion into therapeutics R&D with new CEO and $20M in VC funding OncoResponse raises $40M for cancer patient-sourced antibodies Xenon frees itself of some XEN1101 milestone obligations This gene mutation is key to glioblastoma’s ‘immortality’ and could point to drug targets Featured Story | | | Tuesday, September 11, 2018 After serving as Gilead’s CMO for just six months, Andrew Cheng has taken the top spot at Akero Therapeutics not long after the biotech raised $65 million to move its lead NASH candidate into phase 2 trials. |
|
|
| This week's sponsor is Synteract, Inc. | | | |
Top Stories Tuesday, September 11, 2018 Crescendo Biologics has named Pavel Pisa, M.D., Ph.D., as its chief medical officer. Pisa is the former group head of translational medicine at Roche, where he worked on the development of oncology drugs including Avastin and Gazyva. Monday, September 10, 2018 A federal appeals court handed the Broad Institute a win in a yearslong dispute Monday when it found there was “no interference-in-fact" between CRISPR patents held by Broad and patents sought by the University of California. Tuesday, September 11, 2018 ImmusanT is expanding its vaccine immunotherapy platform to include Type 1 diabetes, following an investment from the JDRF. Monday, September 10, 2018 As it looks to expand into biologics discovery and development, molecule-monitoring company Biodesy announced it has brought in $20 million and appointed a new CEO to help drive industry adoption of its platform that detects real-time changes in protein structures. Tuesday, September 11, 2018 Texas biotech OncoResponse has raised $40 million in second-round financing to develop drugs based on antibodies taken from cancer survivors. Tuesday, September 11, 2018 Xenon has struck a deal with Bausch Health to free itself from milestone and royalty obligations related to epilepsy prospect XEN1101. The agreement sees Xenon pay $6 million upfront to avoid having to hand over up to $40 million in milestones plus royalties down the line. Monday, September 10, 2018 A mutation in a gene regulator called TERT is the most common mutation in glioblastoma, and it gives cancer cells the ability to divide and spread indefinitely. Researchers at the University of California, San Francisco, have discovered a new way to target the mutation and are working with GlaxoSmithKline to develop a drug based on the finding. Resources Sponsored by: Sciformix Are automation, big data and artificial intelligence (AI) a key part of your company’s pharmacovigilance strategy? Read this whitepaper to know what they should be! Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Patheon, part of Thermo Fisher Scientific When developing a parenteral, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages. Sponsored by: Baxter Baxter BioPharma Solutions’ whitepaper offers a method to address the challenges of tech transfer for lyophilized products from lab-scale to commercial-scale. Sponsored by: Catalent In this case study, an unknown leachable species was detected by GC-MS analysis of an alkaline drug product (pH approximately 10.5) that was packaged in a novel self- contained plastic Blow Fill Seal (BFS) vial. Sponsored by: Blue Matter A whitepaper outlining the key commercial challenges facing rare disease products, and how biopharmaceutical companies can overcome them. Sponsored by: AWS and Tableau Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children. Sponsored by: Catalent Catalent provides world class stability services to ease your critical path to success. Sponsored by: AWS and Reltio Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS. Presented by: AWS and Druva Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data. Sponsored by: Health Strategies Group The window of market exclusivity continues to narrow dramatically in the global marketplace. Given this demanding environment, your global market access team faces increasing urgency to get the value proposition right at the time of launch. Drug Approval, Manufacturing Quality & Regulation 2018 | Online 2018 Latin America Healthcare Compliance Certification Program September 24-27, 2018 | Sao Paulo, Brazil Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Compliance Certification Program at Seton Hall Law October 8-11, 2018 | Newark, NJ BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL Fierce Innovation Awards: Life Sciences Edition 2018 FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Understanding Commercialization Within Biopharma Nov 7-8, 2018 | Boston, MA Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation Drug Development Immersion December 5-6, 2018 | San Diego, CA Understanding Drug Pricing and Reimbursement December 12, 2018 | Boston, MA | 